Rakuten Medical, Inc. is a global biotechnology company founded in 2010, dedicated to developing and commercializing precision cell-targeting therapies through our proprietary Alluminox™ platform. Alluminox™ platform is an investigational photoimmunotherapy developed by Dr. Hisataka Kobayashi and team from the National Cancer Institute in the United States. Rakuten Medical’s lead asset, ASP-1929, is an antibody-dye conjugate comprised of the antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 has received Fast Track designation from the U.S. FDA in January 2018, and is currently under investigation in a global Phase 3 clinical trial for recurrent head and neck cancer. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020,.